Navigation Links
Compound Reverses Huntington's Symptoms in Mice
Date:9/16/2008

Treatment slowed reduction of brain size, improved motor functioning, study finds

TUESDAY, Sept. 16 (HealthDay News) -- An experimental compound called HDACi 4b reversed Huntington's disease symptoms in mice genetically altered to develop the disease, say researchers at the Scripps Research Institute in California.

Huntington's is an inherited neurological disease that affects people's movement and thinking ability. There is no cure or treatment that can reverse or slow progression of the physical and mental deficits caused by the disease.

"We found that (HDACi 4b) can target the expression of several hundred genes in the brain and reverse the abnormalities caused by a single mutant protein. This suggests that a treatment for Huntington's disease that targets a core pathogenic mechanism might be close at hand -- closer than previously imagined," study author Elizabeth A. Thomas, an assistant professor in department of molecular biology, said in a Scripps news release.

In this study, the mice were given the compound after they first started to develop symptoms of Huntington's. The treatment slowed the loss of body weight and reduction of brain size, and improved their appearance and motor functioning.

"The benefit seen was surprising, and immensely exciting, because it suggests this compound could form the basis of truly relevant therapeutic treatment for Huntington's disease," Thomas said. "The mice that were destined to develop Huntington's disease receiving the treatment did significantly better than the mice who didn't receive the drug."

The findings were published this week in the early edition of the Proceedings of the National Academy of Sciences. The study received funding from Massachusetts-based Repligen Corp., which holds several patent applications related to HDAC (histone deacetylase) inhibitors, a class of agents that include HDACi 4b.

Other HDAC inhibitors produced some beneficial results in test animals but were deemed too toxic.

"[HDACi 4b] proved to be therapeutically superior, as well as less toxic than other HDAC inhibitors that had been tested for Huntington's disease," Thomas said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Huntington's disease.



-- Robert Preidt



SOURCE: Scripps Research Institute, news release, Sept. 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coloring Compound in Fruits, Veggies May Cut Colon Cancer Risk
2. Sugary Sodas High in Diabetes-Linked Compound
3. Red wine compound shown to prevent prostate cancer
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
8. Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding
9. Cannabis Compound May Stop Metastatic Breast Cancer
10. Prostate Cancer Treatments Often Compound Existing Health Problems
11. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: